Survey: técnica para realização de injeção intravítrea pelos membros da Sociedade Brasileira de Retina e Vítreo (SBRV) by Shiroma, Helio Francisco et al.
Original Article 
32 Arq Bras Oftalmol. 2015;78(1):32-5 http://dx.doi.org/10.5935/0004-2749.20150009
INTRODUCTION
The intraocular application of antiangiogenic drugs through in-
travitreal injection (IVI) has changed the natural progression of many 
retinal diseases during the past 10 years. The treatment of retinal 
diseases began with the use of pegaptanib (Macugen®, Valeant, 
Canada) and was followed by the use of bevacizumab (Avastin®, 
Roche, Switzerland), as reported by Phillip Rosenfeld (2005)(1,2). At 
present, two antiangiogenic drugs have been approved by the Brazi-
lian National Health Surveillance Agency (ANVISA) for intravitreal use: 
ranibizumab (Lucentis®, Novartis Switzerland) and aflibercept (Eylia®, 
Bayer HealthCare Pharmaceuticals, Germany).
The IVI of antiangiogenic drugs is intended to transiently decrea-
se the amount of vascular endothelial growth factor (VEGF). VEGF 
is responsible for the alterations observed during diseases such as 
age-related macular degeneration (AMD), diabetic macular edema, 
and central retinal vein occlusions (CRVO) or branch retinal vein 
occlusions (BRVO). The pain experienced by patients is considered to 
be mild(3), and the procedure can be performed under topical anes-
thesia or nerve block, with or without venous sedation.
The technique, operative precautions, and the area where the 
procedure is performed differ according to each surgeon and according 
to different standards adopted in each country. Green-Simms et al. 
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ABSTRACT
Objective: To evaluate and describe the precautions involved in the technique 
of intravitreal injection of antiangiogenic drugs adopted by the ophthalmologists 
who are members of the Brazilian Society of Retina and Vitreous (SBRV). 
Method: A questionnaire containing 22 questions related to precautions taken 
before, during, and after intravitreal injection was sent electronically to 920 mem-
bers of SBRV between November 15, 2013 and April 31, 2014. 
Results: 352 responses (38%) were obtained. There was a predominance of men 
(76%) from the southwest region of Brazil (51%). The professional experience varied 
between 6 and 15 years after medical specialization (50%). Most professionals (76%) 
performed an average of 1 to 10 intravitreal injections a week, and 88% of the 
procedures were performed in the operating room using povidone iodine (99%), 
sterile gloves, and blepharostat (94%). For inducing topical anesthesia, usage of 
anesthetic eye drops was the most used technique (65%). Ranibizumab (Lucentis®) 
was the most common drug (55%), and age-related macular degeneration (AMD) 
was the most treated disease (57%). Regarding the complications treated, 6% of 
the ophthalmologists had treated at least one case of retinal detachment, 20% had 
treated cases of endophthalmitis, 9% had treated cases of vitreous hemorrhage, 
and 12% had encountered cases of crystalline lens touch. 
Conclusion: Intravitreal injection is a procedure routinely performed by retina 
specialists and has a low incidence of complications. Performing the procedure 
in the operating room using an aseptic technique was preferred by most of the 
respondents. Ranibizumab was the most used drug, and AMD was the most 
treated disease.
Keywords: Intravitreal injections; Retinal diseases; Angiogenesis inhibitors; Topical 
anesthesia 
RESUMO
Objetivo: Avaliar e descrever os cuidados envolvidos durante o procedimento de in jeção 
intravítrea de drogas antiangiogênicas realizado pelos oftalmologistas membros da 
Sociedade Brasileira de Retina e Vítreo (SBRV).
Método: Foi enviado um questionário aos 920 membros da SBRV, por meio de correio 
eletrônico, entre o período de 15/11/2013 a 31/04/2014, contendo 22 questões, rela-
cionado aos cuidados pré, intra e pós-operatório da injeção intravítrea.
Resultados: Foram obtidas 352 respostas (38% dos sócios). Houve um predomínio 
do sexo masculino (76%), procedentes da região Sudeste (51%). O tempo de experiên-
cia profissional se concentrou entre 6 a 15 anos após o término da especialização 
(50%). A maioria dos participantes tem média semanal de 1 a 10 (76%), sendo 88% 
das vezes realizado dentro do centro cirúrgico, utilizando iodopovidona (99%), luvas 
e blefarostato estéreis (94%). A anestesia tópica com colírio anestésico foi a técnica 
mais utilizada (65%). Entre os participantes, ranibizumabe (Lucentis®) é a droga mais 
utilizada (55%) e a degeneração macular relacionada a idade (DMRI) é a doença mais 
tratada (57%). Das complicações citadas pelos oftalmologistas, 6% já vivenciaram 
pelo menos um caso de descolamento de retina, 20% endoftalmite, 9% hemorragia 
vítrea e 12% toque cristaliniano. 
Conclusão: A injeção intravítrea é um procedimento realizado rotineiramente por 
retinólogos, com baixo índice de complicações. A realização do procedimento no 
centro cirúrgico com técnica asséptica é preferida pelos pesquisados. A droga mais 
utilizada foi o ranibizumabe e a doença mais tratada foi a DMRI.
Descritores: Injeções intravítreas; Doenças retinianas; Inibidores da angiogênese; Anes -
tesia tópica
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described the technique used for IVI in the United States(4). In June 
2014, retina specialists described the technique used for IVI in Cana-
da(5). However, we have not found any study describing the technique 
used for IVI in Brazil.
The objective of this study was to assess and describe the precau-
tions, techniques, and materials used by ophthalmologists who are 
members of the Brazilian Society of Retina and Vitreous (Sociedade 
Brasileira de Retina e Vítreo; SBRV) for IVI. 
METHODS
A descriptive questionnaire was created for specialists in the field 
of the retina and vitreous. This questionnaire was approved by the 
Research Ethics Committee of UNIFESP under protocol No. 132244.
Data were collected using a questionnaire containing 22 queries 
regarding epidemiological data; the anesthetic technique used; 
precautions adopted before, during, and after surgery; and the cal-
culation of the incidence of complications. Questionnaires were sent 
electronically to 920 SBRV members between November 15, 2013 
and April 31, 2014 and were sent at two other occasions to profes-
sionals who did not respond to the first invitation. The answers were 
compiled and analyzed using the Survey Monkey method(6) (Palo 
Alto, California, USA). The variable results were expressed as relative 
frequencies. Only questionnaires answered in full were evaluated. 
The confidentiality of the participants was maintained during all 
stages of the study, and it was not possible to match the participants 
with their responses.
RESULTS
A total of 352 SBRV members (38%) responded to the question-
naire and herein will be referred to as the study participants. There 
was a predominance of men (76%) responding to this questionnaire. 
With regard to the period of professional experience after retina spe-
cialization, 20% of the respondents had ≤5 years of experience, 25% 
had 6-10 years of experience, 25% had 11-15 years of experience, 13% 
had 16-20 years of experience, 11% had 21-30 years of experience, 
and 6% had >31 years of experience.
Of the study participants, 51% were located in the southeast of 
Brazil, 18% in the northeast, 18% in the south, 10% in the midwest, 
and 2% in the north. Moreover, 46.02% of the participants worked ex-
clusively in the private sector, 1.42% in the public sector, and 52.56% 
in both sectors. With regard to the type of health care provided to 
the patients, 38% of the patients were assisted in private clinics, 52% 
used health care plans, and 10% used the Unified Health System 
(SUS) (Table 1).
The location chosen to perform the IVI procedures was the ope-
rating room (88.10%), ophthalmic clinics (5.10%), and in minor pro-
cedure rooms (6.80%). The mean number of IVI procedures per week 
performed by the study participants was as follows: 1-10 injections 
(76.10%), 11-20 injections (16.40%), 21-30 injections (4.20%), 31-40 
injections (1.70%), and >40 injections (1.40%). Povidone iodine was 
used in 99.10% of the cases whereas sterile gloves, drapes, and ble-
pharostat were used in 94.80% of the cases. Sterile drapes were used 
by 39.40% of the professionals. 
For anesthesia, topical anesthesia with anesthetic eye drops was 
the most widely used technique (used by 67% of the participants), 
followed by anesthetic eye drops with anesthetic gel (20%), and pe-
ribulbar nerve block (3%). Approximately 12% of the respondents 
reported having used intravenous sedation. 
Most retina specialists (80%) used a compass to measure the 
distance of the limbus. Moreover, tunneling and conjunctival displa-
cement were performed by 30% and 58% of the professionals, res-
pectively. Intravitreal injection in both eyes was performed on the 
same day by 36% of the respondents when necessary. With regard 
to the type of needle/syringe used, 43% used the syringe that came 
with ranibizumab whereas 48% used a syringe attached to an ultra-
fine needle (BD ultrafine® needle, Becton, Dickinson, and Company, 
New Jersey, USA).
Furthermore, 5% of the participants used hypotensive eye drops, 
10% used acetazolamide, and 3% used compression of the eyeball 
with a Honan balloon in the preoperative period; 30% of the parti-
cipants had never performed paracentesis whereas 54% reported 
having performed the procedure when necessary.
AMD was the most common disease treated (57%), followed by 
diabetic macular edema (27%), retinal vein occlusion (14%), and other 
pathologies (2%). Ranibizumab was the most widely used drug among 
the participants (55%), followed by bevacizumab (35%), and afliber-
cept (10%) (Table 2). 
With regard to the AMD treatment protocols, 30% of the partici-
pants preferred the Pro Re Nata (PRN) approach (7), 26% preferred the 
“treat and extend” approach(8), and 12% preferred the monthly appli-
cations. One-third of the participants used one of these treatment 
regimens, depending on individual patients.
Postoperative evaluation was conducted on the same day by 
7% of the participants, on the first day postoperatively (PO) by 39%, 
within 3-7 days PO by 24%, within 7-14 days PO by 9%, and within 
14-30 days PO by 21%. The use of antibiotic eye drops for 3-7 days PO 
was prescribed by 89.21% of the professionals. 
In the postoperative period, mild punctate keratitis was the most 
frequent complication, which was reported to be encountered by 
62% of the participants. Most (65%) of the participants reported 
having encountered no serious complications, 20% reported having 
treated at least one case of endophthalmitis, 6% had treated cases 
Table 1. Profile of the respondents
Study population Characteristics % of responses
Gender Male 76
Female 24
Work experience after specialization 0-5 years 20
6-10 years 25
11-15 years 25
16-20 years 13
21-31 years 11
>31 years 06
Health care service Private 46
Public 01
Both 53
Number of weekly injections 1-10 76
11-20 16
21-30 04
31-40 02
>40 02
Region where the procedure was 
performed
South 18
Southeast 51
Midwest 10
North 02
Northeast 19
Place of treatment Surgical center 88
Medical clinic 12
Health care service used by the patient Unified health system 10
Private clinics 38
Health care plan 52
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of retinal detachment, 9% had treated cases of vitreous hemorrhage, 
and 12% had treated cases of crystalline lens touch (Table 3).
DISCUSSION
The subspecialty of retina and vitreous care has attracted the in-
terest of young ophthalmologists because of considerable advances 
in diagnostic and surgical equipment and because of novel therapies 
against diseases that would invariably have progressed to blindness. 
Although the questionnaires were sent repeatedly to all SBRV 
members, only 38% responded, and this low response rate introdu-
ced a source of bias that precluded the generalization and interpre-
tation of data. However, a great merit of the present study was the 
description of the IVI technique adopted by a representative sample 
of the ophthalmologists, and the responders may have included the 
most active members of the SBRV. 
Men predominated (76%) among the study participants, and most 
questionnaires came from the southeast region, which has the lar-
gest concentration of specialists. Specialists with various levels of 
professional experience participated, including recently graduated 
doctors (20%) and professionals with >30 years experience (6%), with 
an average of 6-15 years of experience.
Most retina specialists performed an average of 1-10 IVIs a week, 
and 88% of the procedures were performed in the operating room. 
The medical clinic was chosen for the procedure by only 12% of the 
respondents, in contrast to the results of large studies such as those 
conducted by the Comparison of Age-related Macular Degeneration 
Treatments Trials (CATT), involving 12,886 injection procedures and 
the retrospective study by Cheung et al., involving 14,895 injection 
procedures, wherein all procedures were performed in the clinic (9). 
Sterile surgical materials, povidone iodine, and topical eye drops 
during patient preparation were used in approximately 99% of the 
cases. Until date, there is no consensus on the use of sterile drapes. 
In the present study, it was used in <40% of the cases in an attempt 
to decrease the risk of endophthalmitis. In the U.S., gloves are not 
mandatory, and syringes do not need to be sterile, but the tip of 
any surgical instrument should remain sterile until it touches the 
pa tient’s eye(4).
The most used anesthetic technique was topical anesthesia with 
eye drops or gels, with or without compression using cotton swabs. 
However, intravenous sedation conducted by anesthesiologists can 
provide comfort and reassurance to patients and the surgeon. On the 
other hand, the disadvantages of intravenous sedation include the 
risks associated with CNS depressant drugs, high cost of the proce-
dure, and increased length of hospitalization(10).
The application site was demarcated using a compass in 80% 
of the cases. The most used syringe was BD ultrafine® in 48% of the 
cases. One reason for preferring the use of small-volume syringes is 
the accuracy in adjusting the drug volume, which is directly related 
to treatment efficacy and response variability(11).
Precautions involving intraocular pressure (IOP) during the posto-
perative period were not very relevant among the physicians, con-
sidering that 48% of the respondents did not measure IOP after the 
procedure. A study by Yannuzzi et al. (2014) based on a questionnaire 
sent to retina specialists suggested that the sustained increase in IOP 
after IVI was directly associated with the volume and rate of injection 
of the drug. Accordingly, patients who received volumes of >0.05 cm3 
injected in less than one s showed 5.56 times more likelihood of ha-
ving ocular hypertension due to potential damage of the trabecular 
meshwork(12). The use of oral or ocular hypotensive eye drops was 
reported by <10% of the respondents. Previous studies have shown 
that scleral compression using cotton swabs containing anesthetic(13) 
or the use of a Honan balloon(14) can dehydrate the vitreous and 
lower IOP, thereby avoiding peaks during the immediate postopera-
tive period. In the present study, paracentesis was performed when 
necessary by 54% of the respondents, whereas 31% reported never 
having used this procedure. The Diabetic Retinopathy Clinical Research 
Network (DRCR.net) was founded in 2002 by the National Institute of 
Health with the aim of performing multicenter studies in 200 cities 
across the U.S., Europe, and Asia and defining the best treatment for 
diabetic retinopathy and macular edema using IVI. However, DRCR.
net did not require the measurement of IOP and only assessed visual 
acuity and optic nerve perfusion using indirect ophthalmoscopy(14). 
In our study, 25% of the respondents reported having assessed the 
optic nerve perfusion, and 25% measured IOP after the procedure. 
With regard to postoperative complications, 65% of the profes-
sionals reported not having encountered any serious complications 
related to IVIs during their professional career. Among the ophthal-
mologists who encountered at least one case with complications, 
retinal detachment and crystalline lens touch may have been asso-
ciated with the inadvertent movement of the patient during the 
pro cedure. Endophthalmitis is another serious complication, and 20% 
Table 2. Techniques and precautions adopted during intravitreal 
injection
Surgical step Technique % of responses
Preoperative precautions Use of povidone iodine 99
Sterile gloves 95
Sterile drapes 40
Blepharostat 95
Ocular hypotensive drug 18
Anesthetic technique used Topical eye drops 67
Anesthetic gel 20
Peribulbar nerve block 03
Paracentesis procedure Never performed 35
Always performed 11
Performed when necessary 54
Postoperative evaluation On the same day 07
1 day PO 39
2-7 days PO 24
8-14 days PO 9
15-30 days PO 21
Pathologies treated Age-related macular degeneration 57
Diabetic edema 27
Retinal vein occlusion 14
Others 02
Drugs used Aflibercept 10
Bevacizumab 35
Ranibizumab 55
PO= postoperatively.
Table 3. Percentage of participants who encountered complications 
associated with intravitreal injection during their professional career
Complication Frequency
Endophthalmitis 20.2%
Retinal detachment 06.3%
Vitreous hemorrhage 09.4%
Crystalline lens touch 11.6%
No complications 065.0%
Shiroma HF, et al.
35Arq Bras Oftalmol. 2015;78(1):32-5
of the respondents had encountered this situation. However, the 
reported incidence of this complication is <0.10% (15,16) and cannot be 
compared with the benefits provided by the treatment(17).
The most used drugs were ranibizumab (55%), followed by be-
vacizumab (35%), and aflibercept (10%). Ranibizumab was the first 
antiangiogenic drug registered by ANVISA for retinal diseases. Bevaci-
zumab is still used off-label in Brazil but less frequently than in the U.S. 
In the present study, it was used in 61% of the cases of AMD, in 62% 
of the cases of CRVO, and in 64% of the cases of BRVO(18). Aflibercept 
is being used increasingly by ophthalmologists and was released in 
Brazil in early 2013. Further studies should indicate possible changes 
in the pattern of use of antiangiogenic drugs in Brazil.
The use of antibiotics in the postoperative period is prevalent (89%) 
in Brazil, although several studies have reported the low incidence 
of endophthalmitis together with possible selection of resistant 
pathogens(19). The fact that the indication for endophthalmitis is 
mentioned on the package leaflet as well as legal aspects may explain 
their exaggerated use. The DRCR.net does not impose the use of 
antibiotics(20) in the postoperative period, and they should be used at 
the discretion of each doctor. In 2011, a study reported 5 cases of en-
dophthalmitis after 6251 applications of ranibizumab in the form of 
eye drops. Furthermore, a clinical study published in 2009 evaluated 
the incidence of endophthalmitis after the injection of ranibizumab 
or triamcinolone in patients with diabetic retinopathy and found a 
low incidence of endophthalmitis (0.09% with ranibizumab and no 
incidence with triamcinolone) along with blepharostat and povido-
ne iodine without the need for topical eye drops, antibiotics, sterile 
gloves, or sterile drapes(21).
In summary, despite the limitations of our study with respect to the 
moderate participation of retina specialists who are SBRV members, 
we can conclude that IVI is a common and standardized procedure 
with low risk of complications. The performance of IVI in surgical 
centers and the precautions involving sterile equipment are evident 
in Brazil. Among the respondents, ranibizumab was the most used 
drug, and AMD was the most treated disease.
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